MOVANTIK™ (naloxegol)

Therapeutic Area Nektar
Discovered
Indication Phase Partner
CNS/Pain
MOVANTIK™ Tablets CII (naloxegol) Opioid-induced constipation in adults patients with chronic, non-cancer pain
Approved in US
AstraZeneca
MOVENTIG® (naloxegol) Opioid-induced constipation
Filed in EU
AstraZeneca
NKTR-119
(naloxegol fixed-dose combination product)
Analgesic for pain
Preclinical
AstraZeneca

About MOVANTIK™ (naloxegol) CII Tablets
For information on the recent U.S. FDA approval of MOVANTIK, please visit: http://www.astrazeneca-us.com/media/press-releases/Article/20140916-fda-approves-movantik-naloxegol-tablets-cii.

MOVENTIG® (naloxegol) has been filed for regulatory approval in the European Union.

About Nektar and AstraZeneca Agreement
In September 2009, AstraZeneca and Nektar Therapeutics entered into a worldwide agreement for naloxegol. Under Nektar’s agreement with AstraZeneca, AstraZeneca is responsible for development and commercialization. Nektar is eligible to receive up to $235 million in aggregate payments upon the achievement of certain regulatory and launch milestones, as well as additional tiered sales milestone payments of up to $375 million. Nektar will also be eligible to receive significant double-digit royalty payments on net worldwide sales. The agreement also covers NKTR-119, which is an early stage drug development program that is intended to combine naloxegol with selected opioids. For NKTR-119, Nektar is eligible for additional development milestone payments, tiered sales milestone payments and significant double-digit royalty payments on net sales worldwide.

MOVANTIK is a trademark and MOVENTIG is a registered trademark of the AstraZeneca group of companies.

 
Site Map Privacy Terms of Use Compliance Policy Trademarks Site Users Guide